去整合蛋白變異體及其醫藥用途(DISINTEGRIN VARIANTS AND PHARMACEUTICAL USES THEREOF)
  ‧ 專利名稱 去整合蛋白變異體及其醫藥用途(DISINTEGRIN VARIANTS AND PHARMACEUTICAL USES THEREOF)
  ‧ 專利證書號 -
  ‧ 專利權人 台大(50%)、成大(50%)
  ‧ 專利國家
    (申請日)
PCT (2007/12/21)
中國 (2007/12/21)
歐洲 (2007/12/21)
加拿大 (2009/06/09)
巴西 (2009/06/25)
日本 (2009/06/25)
以色列 (2009/06/25)
墨西哥 (2009/06/26)
澳洲 (2009/06/26)
印度 (2009/07/07)
俄羅斯 (2009/07/24)
韓國 (2009/07/24)
香港 (2010/03/30)
  ‧ 發明人 莊偉哲, 符文美, 黃德富, 黃溫雅, 湯智昕, 陳秋月,
 
技術摘要:
Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin αvβ3 receptor-antagonist activity and substantially reduced integrin αllbβ3 and/or α5β1 receptor-blocking activity as compared to a wild-type disintegrin. The variant is encoded by a modified disintegrin nucleotide sequence that encodes a modified amino acid sequence, resulting in a polypeptide having substantially reduced affinity to integrin αllbβ3 and/or α5β1 as compared to a wild-type disintegrin. The variant is useful for treatment and/or prevention of αvβ3 integrin-associated diseases in a mammal, which include osteoporosis, bone tumor or cancer growth, angiogenesis-related tumor growth and metastasis, tumor metastasis in bone, malignancy-induced hypercalcemia, angiogenesis-related eye diseases, Paget's disease, rheumatic arthritis, and osteoarthritis. The angiogenesis-related eye diseases include age-related macular degeneration, diabetic retinopathy, corneal neovascularizing diseases, ischaemia-induced neovascularizing retinopathy, high myopia, and retinopathy of prematurity.



聯繫方式
聯絡人: 研發處產學合作總中心 電話: (02)3366-9949
地 址: 10087台北市中正區思源街18號 臺大水源校區思源樓3樓